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Abstract
Gene therapy is a therapeutic approach that is designed to correct specific molecular
defects that contribute to the cause or progression of cancer. Genes that are mutated or
deleted in cancers include the cancer susceptibility genes p53 and BRCA1. Because
mutational inactivation of gene function is specific to tumor cells in these settings, cancer
gene correction strategies may provide an opportunity for selective targeting without
significant toxicity for normal nontumor cells. Both p53 and BRCA1 appear to inhibit cancer
cells that lack mutations in these genes, suggesting that the so-called gene correction
strategies may have broader potential than initially believed. Increasing knowledge of cancer
genetics has identified these and other genes as potential targets for gene replacement
therapy. Initial patient trials of p53 and BRCA1 gene therapy have provided some
indications of potential efficacy, but have also identified areas of basic and clinical research
that are needed before these approaches may be widely used in patient care.
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Introduction
Because cancer is a somatic genetic disease, it should
not be surprising that many gene therapy protocols have
been designed to treat various forms of cancer. Even
hereditary cancer syndromes generally include a required
somatic gene alteration. For example, patients with heredi-
tary breast and ovarian cancer due to BRCA1 mutations
are born with a mutation in one BRCA1 allele, but only
develop cancer after mutation or allelic loss of the other
BRCA1 allele. Thus, the complete genetic disorder is only
present in the tumor cells that are targeted for somatic
gene therapy. This is in contrast to inherited germline dis-
eases, in which the genetic defect is present in all cells.
One strategy for cancer gene therapy is that of genetic
correction. Because known gene defects are present
exclusively in the cancer cells, genetic correction thera-
pies provide a potential rational therapy that is molecularly
targeted to cancer cells, but should not necessarily affect
normal nonmalignant cells. A number of genetic correction
strategies have been designed to treat cancer, including
correction of p53 and BRCA1 [1•,2,3]. This review dis-
cusses some of the scientific information related to
genetic correction strategies and then describes animal
models and patient trials designed to initially test this ther-
apeutic approach.
p53 gene therapy
p53 is the most commonly mutated tumor suppressor
gene in solid tumors and is also mutated in the germline of
patients with the rare hereditary Li-Fraumeni syndrome [4].
The p53 gene is specifically relevant to the developmenthttp://breast-cancer-research.com/content/2/1/028
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and progression of breast cancer, because p53 is fre-
quently mutated in breast cancer specimens and Li-Frau-
meni syndrome patients develop breast cancer as part of
their multiple cancer syndrome [4]. Thus, p53 genetic cor-
rection is a rational approach for breast cancer, particu-
larly in those rare patients with breast cancer as part of
Li-Fraumeni syndrome. The function of wild-type p53 is
suppression of cell proliferation through a multiprotein reg-
ulatory pathway that is focused around the retinoblastoma
gene and control of apoptosis [5]. Because p53 may natu-
rally function as an inhibitor of cell proliferation, it inhibits
cell growth in most normal and malignant cells [6,7], with
few exceptions [8]. For this reason it may effectively inhibit
tumor growth even in cancers that do not have p53 muta-
tions [6,7]. Preclinical animal studies of adenovirus-based
p53 gene therapy for cancer in both cell culture and
animal models [9–11] have demonstrated tumor suppres-
sion. Clinical trials of p53 gene therapy for lung cancer
[1•,12•] have been reported, and these studies demon-
strate gene transfer of adenoviral-p53, induction of apop-
tosis, and some indication of therapeutic response. In a
phase 1 clinical trial of nonsmall cell lung cancer [12•], 8%
of treated patients showed a partial response and 64% of
patients showed disease stabilization ranging in duration
from 2 to 14 months.
BRCA1 gene therapy
Although the molecular function of BRCA1 is controversial
and may include DNA repair or transcriptional functions
[13], overexpression of BRCA1 into sporadic breast or
ovarian cancer cells, which usually show low BRCA1
expression [14], results in growth inhibition and tumor sup-
pression [15–23]. Growth inhibition by BRCA1 has itself
been controversial, leading some to question the rationale
for BRCA1 gene therapy [24], but subsequent studies
have shown growth inhibition or tumor suppression by
BRCA1 in vitro [16,17,19–23] and in vivo [15,17,21,25].
The mechanism of growth inhibition by BRCA1 is unknown
and may involve interactions with WAF1/CIP1 [16], p53
[17], Rb [23] or induction of apoptosis [18,19].
Although BRCA1 is only mutated in a small percentage of
breast or ovarian cancers, the majority of sporadic breast
and ovarian cancers appear to express low levels of
BRCA1 messenger RNA and protein [14,26–30]. This
appears to be a consequence of loss of heterozygosity
and promoter methylation of the remaining BRCA1 allele
[14,26–35]. This finding is important because it indicates
that restoration of normal ‘wild-type’ BRCA1 expression
levels in many sporadic cancers may inhibit tumors by a
‘genetic correction’ strategy, wherein the loss of BRCA1
expression contributes to tumorigenesis. These results
constitute the scientific basis for testing BRCA1 gene
therapy in patients with sporadic breast, ovarian, and
prostate cancers that lack specific point mutations in the
BRCA1 gene.
Several different BRCA1 viral vectors have been con-
structed and tested for efficacy in preclinical xenograft
models of breast and ovarian cancer. Initial studies of a
BRCA1 retroviral vector employed a complementary DNA
that encoded a splice variant vector that eliminates the
first 71 amino acids of the human protein, termed
BRCA1sv [2,25,36•]. Studies of both growth inhibition
and DNA repair do not identify cellular or molecular differ-
ences between BRCA1sv and BRCA1 complementary
DNAs [36•,37–40]. Intaperitoneal injection of either
BRCA1sv or a full-length BRCA1 retroviral vector into
ovarian cancer or breast cancer xenografts in nude mice
produces tumor inhibition [2,15,25,36•,37–39]. These
studies show that treatment of established SKOV3 or
PA-1 ovarian cancer nude mice xenografts with either the
full-length or the splice variant BRCA1 retroviral vector
results in tumor suppression. Necropsies showed that
PA-1 tumor-bearing mice treated with control media or
low-dose LXSN-BRCA1sv died with large intra-abdominal
tumors and ascites, whereas mice with high-dose
LXSN-BRCA1sv treatments died of lung metastasis with
significantly smaller abdominal tumor. The PA-1 tumor
model is an established xenograft model for ovarian
cancer [37–39,41,42].
The published phase 1 trial of BRCA1sv retroviral gene
therapy [2] demonstrated gene transfer and expression of
the intraperitoneally injected LXSN-BRCA1sv vector. The
vector was moderately stable in the peritoneum of these
patients, and antibody formation was rare. The phase 2
trial performed in a group of patients with lower tumor
burdens [36•], however, demonstrated that tumor size and
immune status strongly influence patient response to
retroviral vectors, and that vectors packaged in mouse
cells are not sufficiently stable to treat patients with small
volume intraperitoneal ovarian cancer.
Patient model systems for breast and ovarian
cancer
The initial patient trials of p53 and BRCA1 gene therapy
demonstrated the potential for gene therapy, but also
clearly demonstrated both basic and clinical research that
is needed before these therapies can be successful in
patients. Initial human clinical trials of BRCA1 retroviral
gene therapy taught us that the approach was safe, but
that healthy patients developed immune responses
towards retroviral vector therapy that decreased vector sta-
bility and presumably prevented response. Based on this
prior experience, we have redesigned our current human
trials to employ a more immune-resistant MFG-based retro-
viral vector that is packaged in human producer cells.
These trials should demonstrate whether this new genera-
tion of human cell-produced retroviral vector is more stable
in the healthier patients with small volume disease.
Because breast and ovarian cancers exhibit significant bio-
logic and genetic similarities, gene therapies may be initiallyBreast Cancer Research    Vol 2 No 1 Obermiller et al
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tested in the setting of ovarian cancer, employing peri-
toneal injection, and then ultimately tested in a more rele-
vant breast cancer human disease model. Both types of
patient model will be described in the following discussion.
The model system of metastatic ovarian cancer growing
within a confined anatomic space (often bathed in ascitic
fluid) has several advantages in safety and efficacy for
studies of gene transfer into solid tumors. The pathology of
metastasis into peritoneal-lined spaces often consists of
small tumor implants with extravasation of tumor cells into the
surrounding space, potentially allowing a reservoir for deliver-
ing gene transfer vectors to malignant cells. This pattern of
spread is in contrast to other solid tumors such as breast,
lung or melanoma that grow as solid three-dimensional
masses anatomically located in sites that are inaccessible to
currently available vector systems. Ovarian cancer provides a
model system in which regional therapy (intraperitoneal infu-
sion) could be curative in a reasonable percentage of cases.
We have reported [2,36•] that the uptake and expression of
the vectors can be readily assessed in this model system
because direct access to the peritoneal cavity is possible
through an implantable peritoneal catheter.
Because present gene therapy tools preclude systemic
treatment strategies, we are initiating a regional treatment
protocol to test the safety and potential efficacy of a
human producer cell-derived MFG-BRCA1 gene therapy
by studying the effect of BRCA1 retroviral gene transfer
into breast cancer tumors that have recurred on the chest
wall. The study population will consist of women who have
failed one course of standard therapy and have biopsy-
proved metastatic breast cancer involving the chest wall.
Nodular chest wall disease constitutes a particular pattern
of metastatic or recurrent breast cancer that is frequently
resistant to treatment with standard therapy. We have
selected chest wall recurrence of breast cancer for this
study because of accessibility of the tumor both for vector
administration and for biopsy and biologic analysis. Chest
wall nodules will be biopsied and then injected daily for 4
days with MFG-BRCA1 viral vector. The tumors will then
be excisionally biopsied 1–4 weeks later, so that molecu-
lar and cellular studies of gene transfer, expression, and
immune response can be evaluated. Because these
nodules are often multiple, we will inject paired nodules
with a placebo retroviral vector MFG in order to test
directly whether observed effects are gene related or
merely nonspecific effects of retroviral vector injection in
humans. Immunologic and molecular studies will be per-
formed on blood samples and tissue samples to evaluate
immune response and vector pharmacokinetics, as in the
ovarian cancer trial.
Conclusion
Genetic correction strategies are presently being devel-
oped and tested in animal models for human malignancies
and in early patient trials. The cancer susceptibility genes
p53 and BRCA1 have been tested in lung cancer and
ovarian cancer patients, respectively, and have shown
some potential for this antitumor strategy. p53 gene
therapy may be effective even against tumors that lack
p53 mutations, because p53 may function as a growth
inhibitor in a variety of gene transfer settings. The observa-
tion that sporadic breast and ovarian cancers show
decreased BRCA1 expression indicates that BRCA1
gene therapy may be effective even against sporadic
breast or ovarian cancer without BRCA1 gene mutations.
Although initial approaches to human gene therapy
focused on germline inherited diseases, it has become
evident that somatic genetic diseases like cancer repre-
sent appropriate targets for somatic gene therapy.
The clinical application of gene correction therapy will
require advances in both basic science and clinical
research. Key problems at present include the degrada-
tion of vector by the immune system and a need for higher
levels of gene transduction. Solutions will require the
development of improved vectors, improved vector deliv-
ery systems, and the fine-tuning of human gene therapy in
appropriate models of human cancer.
References
Articles of particular interest have been highlighted as:
• of special interest
•• of outstanding interest
1. Roth JA, Nguyen D, Lawrence DD, et al: Retroviral mediated wild-
• type p53 gene transfer to tumors of patients with lung cancer.
Nature Med 1996, 2:985–991.
This is an important initial report of the genetic correction strategy for
cancer gene therapy.
2. Tait DL, Obermiller PS, Redlin-Frazier S, et al: Phase I trial of BRCA1
retroviral gene therapy for ovarian cancer. Clin Cancer Res 1997,
3:1959–1968.
3. Roth JA, Cristiano RJ: Gene therapy for cancer: what have we done
and where are we going? J Natl Cancer Inst 1997, 89:21–39.
4. Malkin D, Li FP, Strong LC, et al: Germ line p53 mutations in a
familial syndrome of breast cancer, sarcomas, and other neo-
plasms. Science 1990,  250:1233–1238.
5. Harris CC: The p53 tumor suppressor gene as a target for new
anticancer therapies. Adv Oncol 1998, 14:3–7.
6. Leach SD, Scatena CD, Keefer CJ, et al: Negative regulation of
Wee1 expression and Cdc2 phosphorylation during p53-mediated
growth arrest and apoptosis. Cancer Res 1998, 58:3231–3236 
7. Pietenpol JA, Tokino T, Thiagalingam S, et al: Sequence-specific
transcriptional activation is essential for growth suppression by
p53. Proc Natl Acad Sci USA 1994, 91:1998–2002.
8. Pietenpol JA, Lengauer C, Jordan J, Kinzler KW, Vogelstein B: Mam-
malian cells resistant to tumor suppressor genes. Proc Natl Acad
Sci USA 1996, 93:8390–8394.
9. Song KM, Cowan KH, Sinha BK: In vivo studies of adenovirus-
mediated p53 gene therapy for cis-platinum-resistant human
ovarian tumor xenografts. Oncol Res 1999, 11:153–159.
10. Santoso JT, Tang DC, Lane SB, et al: Adenovirus-based p53 gene
therapy in ovarian cancer. Gynecol Oncol 1995, 59:171–178.11. von Gruenigen VE, Santoso JT, Coleman RL, et al: In vivo studies of
adenovirus-based p53 gene therapy for ovarian cancer. Gynecol
Oncol 1998, 69:197–204.
12. Swisher SG, Roth JA, Nemunaitis J, et al: Adenovirus-mediated p53
• gene transfer in advanced non-small-cell lung cancer. J Natl
Cancer Inst 1999, 91:763–771.
This is a detailed report of results of treatment of 28 patients with adeno-
virus-p53 therapy for lung cancer.
13. Kinzler KW, Vogelstein B: Gatekeepers and caretakers. Nature
1997,  386:761–763.
14. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT:
Decreased expression of BRCA1 accelerates growth and is often
present during sporadic breast cancer progression. Nature Genet
1996, 9:444–450.
15. Holt JT, Thompson ME, Szabo C, et al: Growth retardation and
tumor inhibition by BRCA1. Nature Genet 1996, 12:298–302.
16. Somasundaram K, Zhang H, Zeng YX, et al: Arrest of the cell cycle
by the tumour-suppressor BRCA1 requires the CDK-inhibitor
p21WAF1/CiP1.  Nature 1997, 389:187–190.
17. Zhang H, Somasundaram K, Peng Y, et al: BRCA1 physically associ-
ates with p53 and stimulates its transcriptional activity. Oncogene
1998, 16:1713–1721.
18. Shao N, Chai YL, Shyam E, Reddy P, Rao VN: Induction of apoptosis
by the tumor suppressor protein BRCA1. Oncogene 1996, 13:1–7.
19. Harkin DP, Bean JM, Miklos D, et al: Induction of GADD45 and
JNK/SAPK-dependent apoptosis following inducible expression
of BRCA1. Cell 1999, 97:575–586.
20. Humphrey JS, Salim A, Erdos MR, et al: Human BRCA1 Inhibits
growth in yeast: potential use in diagnostic testing. Proc Natl Acad
Sci USA 1997, 94:5820–5825.
21. Burke TF, Cocke KS, Lemke SJ, et al: Identification of a BRCA1-
associated kinase with potential biological relevance. Oncogene
1998, 16:1031–1041.
22. Jensen DE, Proctor M, Marquis ST, et al: BAP1: a novel ubiquitin hydro-
lase which binds to the BRCA1 RING finger and enhances BRCA1-
mediated cell growth suppression. Oncogene 1998, 16:1097–1112.
23. Aprelikova ON, Fang BS, Meissner EG, et al: BRCA1-associated
growth arrest is RB-dependent. Proc Natl Acad Sci USA 1999, 96:
11866–11871.
24. Anonymous: No stranger to controversy [editorial]. Nature Genet
1997, 17:247–248.
25. Holt JT, Thompson ME, Szabo C, et al: Growth retardation and tumor
inhibition by BRCA1 (correction). Nature Genet 1998, 19:102.
26. Mancini DN, Rodenhiser DI, Ainsworth PJ, et al: CpG methylation
within the 5¢ ¢ regulatory region of the BRCA1 gene is tumor spe-
cific and includes a putative CREB binding site. Oncogene 1998, 9:
1161–1169.
27. Rice JC, Massey-Brown KS, Futscher BW: Aberrant methylation of
the BRCA1 CpG island promoter is associated with decreased
BRCA1 mRNA in sporadic breast cancer cells. Oncogene 1998, 17:
1807–1812 
28. Ozcelik H, To MD, Couture J, Bull SB, Andrulis IL: Preferential allelic
expression can lead to reduced expression of BRCA1 in sporadic
breast cancers. Int J Cancer 1998, 77:1–6.
29. Jarvis EM, Kirk JA, Clarke CL: Loss of nuclear BRCA1 expression in
breast cancers is associated with a highly proliferative tumor phe-
notype. Cancer Genet Cytogenet 1998, 101:109–115.
30. Wilson CA, Ramos L, Villasenor MR, et al: Localization of human
BRCA1 and its loss in high-grade, non-inherited breast carcino-
mas. Nature Genet 1999, 21:236–240.
31. Yoshikawa K, Honda K, Inamoto T, et al: Reduction of BRCA1 protein
expression in Japanese sporadic breast carcinomasand its fre-
quent loss in BRCA1-associated cases. Clin Cancer Res 1999,
5:1249–1261.
32. Seery LT, Knowlden JM, Gee JM, et al: BRCA1 expression levels
predict distant metastasis of sporadic breast cancers. Int J Cancer
1999, 84:258–262.
33. Rio PG, Maurizis JC, Peffault de Latour M, Bignon YJ, Bernard-Gallon
DJ: Quantification of BRCA1 protein in sporadic breast carcinoma
with or without loss of heterozygosity of the BRCA1 gene. Int J
Cancer 1999, 80:823–826.
34. Lee WY, Jin YT, Chang TW, Lin PW, Su IJ: Immunolocalization of
BRCA1 protein in normal breast tissue and sporadic invasive
ductal carcinomas: a correlation with other biological parameters.
Histopathology 1999, 34:106–112.
35. Catteau A, Harris WH, Xu CF, Solomon E: Methylation of the BRCA1
promoter region in sporadic breast and ovarian cancer: correla-
tion with disease characteristics. Oncogene 1999, 18:1957–1965.
36. Tait DL, Hatmaker AR, Redlin-Frazier S, Obermiller PS, Holt JT:
• Ovarian cancer BRCA1 gene therapy: phase I & II trial differences
in immune response and vector stability. Clin Cancer Res 1999,
5:1708–1714.
This study compares immune responses to retroviral vector and vector sta-
bility in patients with extensive intraperitoneal tumors versus those with
small volume residual disease.
37. Tait DL, Jones H, Holt JT: Current status of gene therapy for ovarian
cancer. CME J Gynecol Oncol 2000, in press.
38. Tait DL, Jensen RA, Gralow J, et al: Gene therapy for breast and
ovarian cancer with BRCA1. Breast Dis 1998, 10:89–98.
39. Tait DL, Obermiller PS, Jensen RA, Holt JT: Ovarian cancer gene
therapy. Hematol Oncol Clin North Am 1998, 12:539–552.
40. Abbott DW, Thompson ME, Robinson-Benion C, Jensen RA, Holt JT:
BRCA1 expression restores radiation resistance in BRCA1-defec-
tive cancer cells enhancement of transcription coupled DNA
repair.  J Biol Chem 1999, 274:18808–18812.
41. Manetta A, Emma D, Gamboa G, et al: Failure to enhance the in vivo
killing of human ovarian carcinoma by sequentialtreatment with
dequalinium chloride and tumor necrosis factor. Gynecol Oncol
1993,  50:38–44.
42. Yaginuma Y, Westphal H: Abnormal structure and expression of
the p53 gene in human ovarian carcinoma cell lines. Cancer Res
1992, 52:4196–4199.
Authors’ affiliations: Jeffrey T Holt and Patrice S Obermiller
(Vanderbilt University Cancer Center, Nashville, Tennessee, USA) and
David L Tait (Division of Gynecologic Oncology, Department of
Obstetrics and Gynecology, East Carolina University School of
Medicine, Greenville, North Carolina, USA)
Correspondence: Jeffrey T Holt, Professor of Cell Biology and
Pathology, Vanderbilt University Cancer Center, 2220 Pierce Avenue
South MRB II 659, Nashville, TN 37232-6838, USA.
Tel: +1 615 936 3114; fax: +1 615 936 1790;
e-mail: jeff.holt@mcmail.vanderbilt.edu
http://breast-cancer-research.com/content/2/1/028
31